Clinical Trial Update: Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating tunlametinib in combination with vemurafenib for BRAF V600E-mutant metastatic colorectal cancer. The study is currently recruiting and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Tunlametinib (tunlametinib)
• Vemurafenib (vemurafenib)

Snippet

Sponsor: Shanghai Kechow Pharma, Inc. | Conditions: Colorectal Cancer Metastatic | Phase 3 | Status: RECRUITING